Related Experiment Videos
Thermochemotherapy in hereditary retinoblastoma
A O Schueler1, C Jurklies, H Heimann
1Department of Ophthalmology, University of Essen, Hufelandstrasse 55, 45122 Essen, Germany. andreas.schueler@uni-essen.de
The British Journal of Ophthalmology
|December 19, 2002
Summary
Thermochemotherapy (TCT) is effective for retinoblastoma tumors under 4mm, but larger tumors have high recurrence rates. Fish flesh regression after TCT indicates a higher risk of recurrence.
Area of Science:
- Ophthalmology
- Pediatric Oncology
- Medical Physics
Background:
- Thermochemotherapy (TCT), combining chemotherapy and transpupillary thermotherapy, is a standard treatment for advanced retinoblastoma.
- This study evaluates the safety, efficacy, and limitations of TCT in retinoblastoma management.
Purpose of the Study:
- To determine safe indications for TCT in retinoblastoma.
- To analyze complications and limitations associated with TCT treatment.
- To identify risk factors for tumor recurrence after TCT.
Main Methods:
- Analysis of tumor response and side effects in 55 retinoblastoma tumors across 26 children treated with TCT.
- Utilized the Reese-Ellsworth classification system for tumor staging.
- Parameters included tumor height/diameter, TCT sessions, laser energy/duration, and chemotherapy regimens (vincristine, etoposide, carboplatin).
Main Results:
- Local recurrence occurred in 38% of tumors, with recurrence risk correlated to tumor height (63% for tumors >4mm).
- Fish flesh regression and increased laser power during TCT were significant risk factors for recurrence.
- Treatment-related complications occurred in less than 9% of treated eyes, including transient corneal opacification and iris atrophy.
Conclusions:
- TCT is efficient for retinoblastoma tumors <4mm in height.
- Larger tumors (>4mm) exhibit unacceptably high recurrence rates.
- Fish flesh regression is a key indicator of higher local tumor recurrence risk post-TCT.